• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Preclinical rationale and phase I clinical trial of the adriamycin analog, AD 32.

作者信息

Blum R H, Garnick M B, Israel M, Panellos G P, Henderson I C, Frei E

出版信息

Recent Results Cancer Res. 1981;76:7-15. doi: 10.1007/978-3-642-81565-2_2.

DOI:10.1007/978-3-642-81565-2_2
PMID:7232854
Abstract
摘要

相似文献

1
Preclinical rationale and phase I clinical trial of the adriamycin analog, AD 32.
Recent Results Cancer Res. 1981;76:7-15. doi: 10.1007/978-3-642-81565-2_2.
2
Clinical strategy for evaluation of anthracycline analogues.蒽环类类似物评估的临床策略
Recent Results Cancer Res. 1980;70:67-73. doi: 10.1007/978-3-642-81392-4_7.
3
Initial clinical evaluation of N-trifluoroacetyladriamycin-14-valerate (AD-32), an adriamycin analog.
Cancer Treat Rep. 1979 May;63(5):919-23.
4
Adriamycin-a review.阿霉素综述
J Natl Cancer Inst. 1975 Dec;55(6):1265-74. doi: 10.1093/jnci/55.6.1265.
5
[Studies on the use of adriamycin in combined treatment of neoplastic diseases].[阿霉素在肿瘤疾病联合治疗中的应用研究]
Atti Accad Med Lomb. 1975;30(1-3):135-40.
6
New anthracycline antibiotic aclacinomycin A: experimental studies and correlations with clinical trials.
Recent Results Cancer Res. 1981;76:21-40. doi: 10.1007/978-3-642-81565-2_4.
7
Quelamycin: a summary of phase I clinical trials.
Recent Results Cancer Res. 1980;74:200-6. doi: 10.1007/978-3-642-81488-4_25.
8
AEZS-108 : a targeted cytotoxic analog of LHRH for the treatment of cancers positive for LHRH receptors.AEZS-108：一种针对 LHRH 受体阳性癌症的靶向细胞毒性 LHRH 类似物。
Expert Opin Investig Drugs. 2012 Jun;21(6):891-9. doi: 10.1517/13543784.2012.685128.
9
The place of pharmacology in cancer medicine.药理学在癌症医学中的地位。
Semin Oncol. 1977 Jun;4(2):131-3.
10
Experimental models and their clinical correlations.实验模型及其临床关联。
Natl Cancer Inst Monogr. 1977 Mar(45):63-74.

引用本文的文献

1
Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021.小分子抑制剂、免疫检查点抑制剂等：1991 年至 2021 年美国食品和药物管理局批准用于实体瘤的新型治疗药物。
J Hematol Oncol. 2022 Oct 8;15(1):143. doi: 10.1186/s13045-022-01362-9.
2
Photophysical characterization of anticancer drug valrubicin in rHDL nanoparticles and its use as an imaging agent.抗癌药物缬柔比星在重组高密度脂蛋白纳米颗粒中的光物理特性及其作为成像剂的应用。
J Photochem Photobiol B. 2016 Feb;155:60-5. doi: 10.1016/j.jphotobiol.2015.12.007. Epub 2015 Dec 18.
3
Use of intravesical valrubicin in clinical practice for treatment of nonmuscle-invasive bladder cancer, including carcinoma in situ of the bladder.
在临床实践中使用膀胱内注射盐酸表柔比星治疗非肌肉浸润性膀胱癌，包括膀胱原位癌。
Ther Adv Urol. 2014 Oct;6(5):181-91. doi: 10.1177/1756287214541798.
4
Phase II study of intravesical therapy with AD32 in patients with papillary urothelial carcinoma or carcinoma in situ (CIS) refractory to prior therapy with bacillus Calmette-Guerin (E3897): a trial of the Eastern Cooperative Oncology Group.AD32膀胱内治疗对卡介苗（BCG）既往治疗难治的乳头状尿路上皮癌或原位癌（CIS）患者的II期研究（E3897）：东部肿瘤协作组的一项试验
Urol Oncol. 2009 Sep-Oct;27(5):496-501. doi: 10.1016/j.urolonc.2008.05.004. Epub 2008 Jul 17.
5
Valrubicin.缬柔比星
Drugs Aging. 1999 Jul;15(1):69-75; discussion 76. doi: 10.2165/00002512-199915010-00006.
6
Antitumor alkylating agents: in vitro cross-resistance and collateral sensitivity studies.抗肿瘤烷化剂：体外交叉耐药性和间接敏感性研究
Cancer Chemother Pharmacol. 1993;33(2):113-22. doi: 10.1007/BF00685328.
7
Pharmacologic studies with radiolabeled N-trifluoroacetyladriamycin-14-valerate (AD 32). Comparison of total anthracycline fluorescence and radioactivity in mouse serum and urine.
Cancer Chemother Pharmacol. 1980;4(2):79-82. doi: 10.1007/BF00254026.
8
Pharmacologic rationale for intravesical N-trifluoroacetyladriamycin-14-valerate (AD 32): a preclinical study.
Cancer Chemother Pharmacol. 1991;28(1):1-6. doi: 10.1007/BF00684948.